However, there is still room for improvement in ensuring a largely indigent population of people with HIV gets access to medical care.

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.

With the HIV population aging, it is increasingly at risk of such age-related cancers.

African-Americans have even lower rates of linkage to and retention in HIV care as well as viral suppression.

This is according to a study of women 18 to 55 years old and their Framingham cardiovascular risk score based on HIV status.

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

Multiple studies have reached this conclusion, raising concerns about sexually transmitted hep C among gay and bi men who have HIV.

Although we have the tools to end the epidemic through treatment and PrEP, costs and other considerations limit these methods.